Andrx Concerta
This article was originally published in The Tan Sheet
Executive Summary
Firm has pending ANDAs for generic versions of McNeil's Rx Concerta (methylphenidare hydrochloride) extended-release tablets in 18, 27, 36 and 54 mg formulations. McNeil's exclusivity for the pediatric hyperactivity deficit disorder drug was set to expire March 17, and the firm has filed a citizen petition with FDA "that affects the timing of, and potentially the approval criteria for, ANDA approvals relating to generic Concerta," according to Andrx. McNeil put 300 sales reps behind the drug in 2000 (1"The Tan Sheet," April 24, 2000, In Brief)...
You may also be interested in...
McNeil
J&J consumer health care division providing 300 reps to detail Alza's pediatric attention hyperactivity deficit disorder Rx drug Concerta following its anticipated late summer launch in the U.S. Approximately 110 McNeil reps will contact pediatricians exclusively, while the rest will detail to general practitioners and family care physicians. Under the agreement with Alza, McNeil will receive payments for its sales efforts and payments based upon specific sales attained. Alza is hoping to leverage McNeil's sales experience in pediatrics with Children's Tylenol and Children's Motrin. The J&J division co-promotes two other Rx drugs: Daiichi's Floxin otic and Allergan's Ocuflox ophthalmic solution
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.